Publications by authors named "Steven McCune"

Claim this Profile
R
Real-world effectiveness of palbociclib plus hormone treatment and its impact on patient quality of life: a plain language summary of findings from POLARIS.
Debu Tripathy, Joanne L Blum, Steven McCune, Timothy Pluard, Daniel Anderson

Future Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving Palbociclib: Biomarker Results From POLARIS Study.
Debu Tripathy, Joanne L Blum, Hong Zhang, Shibing Deng, Steven L McCune

JCO Precis Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer: final results from the POLARIS trial.
Debu Tripathy, Joanne L Blum, Meghan S Karuturi, Steven McCune, Sobha Kurian

Oncologist· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measures of functional status in older patients treated with palbociclib for advanced breast cancer.
Meghan S Karuturi, Joseph C Cappelleri, Joanne L Blum, Kamal Patel, Bijoy Telivala, Steven McCune

J Geriatr Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.
Caicun Zhou, Minu K Srivastava, Hao Xu, Enriqueta Felip, Heather Wakelee, Steven L McCune

J Immunother Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial.
Chung-Han Lee, Robert Motzer, Hamid Emamekhoo, Marc Matrana, Ivor Percent, Steven McCune

Clin Cancer Res· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.
Karim Fizazi, Margitta Retz, Daniel P Petrylak, Jeffrey C Goh, Jose Perez-Gracia, Steven L McCune

J Immunother Cancer· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer.
Caroline Even, Hung-Ming Wang, Shau-Hsuan Li, Roger K-C Ngan, Arunee Dechaphunkul, Steven McCune

Clin Cancer Res· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules.
Georgina V Long, Caroline Robert, Marcus O Butler, Felix Couture, Matteo S Carlino, Steven McCune

Clin Cancer Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
Howard West, Michael McCleod, Maen Hussein, Alessandro Morabito, Achim Rittmeyer, Steven McCune

Lancet Oncol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A recombinant human hemoglobin with anti-sickling properties greater than fetal hemoglobin.
Dana N Levasseur, Thomas M Ryan, Michael P Reilly, Steven L McCune, Toshio Asakura

J Biol Chem· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
Steven L McCune, Jon P Gockerman, Joseph O Moore, Carlos M Decastro, Adam J Bass

Leuk Lymphoma· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis